Skip to content

Clinical trials

Lung Diseases trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases Country / region: China Clear all

66 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20081
20111
20133
20152
20164
20177
20184
20195
20206
20212
20222
20236
202411
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting23
Completed22
Unknown status14
Active, not recruiting5
Enrolling by invitation1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca8
Guangzhou JOYO Pharma Co., Ltd3
Pfizer3
Sichuan Cancer Hospital and Research Institute3
Chinese PLA General Hospital2
Eli Lilly and Company2
Jiangsu HengRui Medicine Co., Ltd.2
Peking University Third Hospital2
RenJi Hospital2
Shanghai Pulmonary Hospital, Shanghai, China2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases66
Respiratory Tract Diseases23
Lung Neoplasms21
Carcinoma, Non-Small-Cell Lung17
Thoracic Neoplasms16
Carcinoma, Bronchogenic13
Neoplasms13
Bronchial Neoplasms12
Pulmonary Disease, Chronic Obstructive11
Neoplasms by Site10

Trials

Showing 76 to 66 of 66. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.